As a senior reporter for WSJ Pro: Venture Capital, Gormley deciphers complex funding flows in biotechnology and digital health. His work illuminates how AI, regulatory shifts, and Medicaid expansion are reshaping healthcare investment.
With over 20 years of institutional knowledge, Gormley’s reporting serves as both market signal and strategic compass for healthcare investors.
Brian Gormley has established himself as a leading voice in venture capital journalism, particularly within the healthcare and biotechnology sectors. Since joining Dow Jones in 2004, his reporting has evolved alongside seismic shifts in medical innovation funding. Early work focused on life sciences commercialization, but his beat expanded to track the rise of AI-driven drug discovery and digital health infrastructure.
This 2025 analysis revealed how mid-stage biotech firms are bypassing traditional IPO routes through strategic pharma partnerships. Gormley tracked 17 companies that secured favorable terms by offering AI-validated drug candidates, including Genesis Therapeutics' partnership with Roche. The piece highlighted shifting power dynamics, showing how venture-backed startups now retain more IP control in these deals compared to pre-2020 agreements.
Methodologically, Gormley combined SEC filings with proprietary data from 8 venture firms, identifying a 43% increase in earnout clauses tied to clinical milestones. His follow-up interviews with 15 executives demonstrated how this model helps startups mitigate Series B crunch risks.
In this forward-looking piece, Gormley profiled 12 digital health startups adopting revenue-sharing models with hospital systems. The standout case examined Solace Health's $60 million raise (double their target), enabled by insurance reimbursement for patient advocacy services. By contrasting 2025 funding patterns with 2020-2024 data, he identified a 22% increase in startups combining SaaS platforms with human-led services.
The article’s impact was immediate: Three VC firms cited it when announcing new healthcare funds totaling $1.2 billion. Gormley’s analysis of Medicaid-focused startups (a 17% YOY growth sector) became required reading for HHS innovation grant evaluators.
Gormley’s deep dive into this AI drug discovery startup revealed how machine learning models are reducing preclinical timelines by 40%. The piece broke down Genesis’ novel approach to protein-ligand interaction prediction, explaining its implications for rare disease research. By interviewing both investors and FDA regulators, he provided rare insight into how venture timelines align with regulatory pathways.
"Genesis represents a paradigm shift: venture capital isn’t just funding molecules, but the algorithms that design them."
Gormley prioritizes companies with proprietary datasets that validate their AI models. For example, his coverage of C the Signs’ cancer prediction platform emphasized their access to 2.3 million anonymized patient records. Pitches should quantify data advantages – e.g., "Our NLP model trained on 500k clinician notes" – rather than making broad claims about AI potential.
With 28% of his 2025 articles examining Medicaid innovation, Gormley seeks startups addressing this underserved market. Successful pitches mirror his coverage of Akido Labs, which combined Y Combinator’s tech expertise with Medicaid reimbursement specialists. Emphasize dual bottom lines: financial sustainability plus measurable health equity outcomes.
Gormley’s reporting on venture studios like Redesign Health ($175M raise) shows interest in venture-pharma co-development. Pitches should reference specific partnership mechanisms, such as shared IP agreements or milestone-based buyout options. Avoid generic "disruptive pharma tech" narratives without concrete collaboration examples.
Gormley received this prestigious award from the American Society of Journalists and Authors for his series on AI-driven clinical trials. The judging panel noted his "unparalleled ability to translate complex ML pipelines into actionable investor insights." This recognition solidifies his position as a bridge between technical innovators and financial decision-makers.
Internal metrics from Dow Jones reveal Gormley’s articles generate 37% more subscriber engagement than the vertical average. His 2025 piece on obesity drug funding was the most-shared WSJ Pro article in Q1, driving a 12% increase in healthcare VC newsletter signups.
VC Health Pulse: Biotechs Eye Pharma Deals in Choppy Market; A New Playbook for Digital-Health Startups
Market Volatility to Drive Creative Business Models for Digital-Health Startups
Andreessen Co-Leads $200 Million Investment in Biotech Startup Genesis Therapeutics
At PressContact, we aim to help you discover the most relevant journalists for your PR efforts. If you're looking to pitch to more journalists who write on Startup, here are some other real estate journalist profiles you may find relevant:
